Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.44 |
| ▸ | NMT1 | P30419 | 6/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3037834 | 0.83 | GBA1 (0.56) | GBA1NMT1SLC6A4GAATSHR | |
| SCHEMBL4771338 | 0.82 | GBA1 (0.49) | GBA1NMT1SLC6A4GAATSHR | |
| SCHEMBL4777240 | 0.81 | GBA1 (0.54) | GBA1NMT1SLC6A4GAATSHR | |
| Hydrochloric Acid SCHEMBL3034504 | 0.81 | GBA1 (0.54) | GBA1NMT1SLC6A4GAATSHR | |
| SCHEMBL4777542 | 0.81 | GBA1 (0.47) | GBA1NMT1SLC6A4 | |
| SCHEMBL27569574 | 0.81 | GBA1 (0.41) | GBA1CHRM2NMT1SLC6A4ADAM17 | |
| Hydrochloric Acid SCHEMBL4777202 | 0.80 | NPSR1 (0.47) | GBA1NMT1GAATSHRHTT | |
| Hydrochloric Acid SCHEMBL4773264 | 0.80 | GBA1 (0.53) | GBA1NMT1SLC6A4GAA | |
| SCHEMBL25145663 | 0.80 | GBA1 (0.56) | GBA1NMT1SLC6A4GAATSHR | |
| SCHEMBL27917814 | 0.80 | GBA1 (0.56) | GBA1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | TSUCHIMORI NOBORU | 2010-08-26 | — | — | US | disclosed |
| US-7348324-B2 | Cyclic amine compounds as CCR5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-25 | — | — | US | disclosed |
| EP-1886994-A1 | Cyclic amine compounds as CCR5 antagonists | Takeda Pharmaceutical Company Limited (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-20050245537-A1 | Use of compounds having ccr antagonism | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | TOBIRA THERAPEUTICS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-6562978-B1 | N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-13 | — | — | US | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | CCR5, CCR1, CCR3 | GBA1 2987/4885CHRM2 152/4885NMT1 661/4885 |
| US-20050245537-A1 | Use of compounds having ccr antagonism | CCR1, CCR3, CCR2 | GBA1 2330/4885CHRM2 947/4885NMT1 1170/4885 |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | CCR1, CCR3, CCR2 | GBA1 2330/4885CHRM2 947/4885NMT1 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.